Literature DB >> 14679043

Kinetic evolution of a diabetogenic CD8+ T cell response.

Pere Santamaria1.   

Abstract

Nonobese diabetic (NOD) mice develop overt diabetes following prolonged periods of pancreatic islet inflammation involving both CD4+ and CD8+ T cells. The initiation and progression of autoimmune diabetes require the recruitment of beta cell-reactive CD8+ T cells to the pancreatic lymph nodes, their activation by antigen, and their subsequent migration into pancreatic islets. We and others have shown that a significant fraction of NOD islet-associated CD8+ T cells express highly homologous TCRalpha chains (Valpha17 and Jalpha42 joined by the same N-region sequence) and that they recognize the peptide NRP-A7 in the context of the MHC class I molecule H-2K(d). We have also shown that this T cell subpopulation undergoes a process of "avidity maturation" that is associated with progression of benign insulitis to overt diabetes. This paper will summarize our current understanding of the mechanisms that drive the recruitment and activation of this CD8+ T cell subpopulation.

Entities:  

Mesh:

Year:  2003        PMID: 14679043     DOI: 10.1196/annals.1288.010

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

Review 1.  Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.

Authors:  Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

2.  The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse.

Authors:  L Shoda; H Kreuwel; K Gadkar; Y Zheng; C Whiting; M Atkinson; J Bluestone; D Mathis; D Young; S Ramanujan
Journal:  Clin Exp Immunol       Date:  2010-05-18       Impact factor: 4.330

3.  Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.

Authors:  Simona Cernea; Kevan C Herold
Journal:  Clin Immunol       Date:  2010-02       Impact factor: 3.969

4.  Characterization of Diabetogenic CD8+ T Cells: IMMUNE THERAPY WITH METABOLIC BLOCKADE.

Authors:  Justin W Garyu; Mohamed Uduman; Alex Stewart; Jinxiu Rui; Songyan Deng; Jared Shenson; Matt M Staron; Susan M Kaech; Steven H Kleinstein; Kevan C Herold
Journal:  J Biol Chem       Date:  2016-03-18       Impact factor: 5.157

5.  High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunity.

Authors:  Gisela M Vaitaitis; David H Wagner
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

6.  Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice.

Authors:  T Alkhamis; J Barbic; T Crnogorac-Jurcevic; R E Greenlaw; M Peakman; S Jurcevic
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.